Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) just unveiled an announcement.
JCR Pharmaceuticals Co., Ltd. announced the distribution of retained earnings as dividends, with a term-end dividend of 10.00 yen per share for the fiscal year ending March 31, 2025, matching the previous year’s dividend. This decision aligns with JCR’s policy of consistent profit distribution while maintaining reserves for new drug development and financial stability.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company focused on expanding possibilities for people with rare and genetic diseases. With a 50-year legacy in Japan, the company is expanding its global presence in the US, Europe, and Latin America. JCR applies scientific expertise and unique technologies to develop next-generation therapies, with approved products in Japan for conditions like growth disorder, MPS II, Fabry disease, and more. The company is also developing investigational products for rare diseases worldwide.
Average Trading Volume: 652,898
Technical Sentiment Signal: Sell
Current Market Cap: Yen58.29B
See more insights into 4552 stock on TipRanks’ Stock Analysis page.